

Pfizer to acquire Array BioPharma in H2

US drug giant Pfizer announced that it is acquiring biotech Array BioPharma for USD 10.64 billion. Pfizer agreed to pay a hefty premium of 62% for Array, which sells the combination treatment Braftovi and Mektovi for melanoma. It is paying USD 48 per share for Array.